positive transcription elongation factor b inhibitor

Positive transcription elongation factor b inhibitor is an unnamed **small-molecule PTEFb inhibitor** described in Vincerx Pharma materials and FDA orphan designation records for hematologic malignancy development. Its intended mechanism is inhibition of **positive transcription elongation factor b**, the **CDK9 cyclin T** transcriptional kinase complex that regulates transcription elongation and expression of short-lived survival and oncogenic proteins such as **MYC** and **MCL1**. Based on the provided context, the program received FDA Orphan Drug Designation on **October 12, 2022** for **diffuse large B-cell lymphoma** and **high grade B-cell lymphoma with MYC and BCL2 rearrangements**, but no distinct nonproprietary name, development code, brand name, dosage form, route, or chemical structure could be confidently identified from the supplied evidence.

Other names

positive transcription elongation factor b inhibitorpositive transcription elongation factor b ptefb inhibitorPTEFb inhibitor